EP Patent

EP3884929A1 — Ocular implant containing a tyrosine kinase inhibitor

Assigned to Ocular Therapeutix Inc · Expires 2021-09-29 · 5y expired

What this patent protects

The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.

USPTO Abstract

The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.

Drugs covered by this patent

Patent Metadata

Patent number
EP3884929A1
Jurisdiction
EP
Classification
—
Expires
2021-09-29
Drug substance claim
No
Drug product claim
No
Assignee
Ocular Therapeutix Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.